Moog Announces Medical Devices Acquisition

EAST AURORA, N.Y., Dec. 30 /PRNewswire-FirstCall/ -- Moog Inc. (NYSE: MOG.A
and MOG.B) announced today that it has acquired 100% of the stock of AITECS
Medical UAB, a Lithuanian-based manufacturer of syringe-style infusion therapy
pumps, for euro 15 million ($21 million), paid in cash. Founded in 1993,
AITECS has a product portfolio that includes pumps for general hospital use,
operating rooms and patient controlled analgesia.

The acquisition complements Moog's current medical devices product line.
"This acquisition is a great fit while broadening our product offering and
geographic presence in the infusion therapy market," said Martin Berardi,
President of the Medical Devices Group of Moog.

Sales for AITECS will be approximately euro 4 million ($6 million) for the
balance of Moog's fiscal year 2009. This acquisition is expected to be
neutral to Moog's earnings per share for the year ending October 3, 2009 due
to first year purchase accounting adjustments.

Moog Inc. is a worldwide designer, manufacturer, and integrator of precision
control components and systems. Moog's high-performance systems control
military and commercial aircraft, satellites and space vehicles, launch
vehicles, missiles, automated industrial machinery, marine and medical
equipment. Additional information can be found at www.moog.com.

Cautionary Statement

Information included herein or incorporated by reference that does not consist
of historical facts, including statements accompanied by or containing words
such as "may," "will," "should," "believes," "expects," "expected," "intends,"
"plans," "projects," "estimates," "predicts," "potential," "outlook,"
"forecast," "anticipates," "presume" and "assume," are forward-looking
statements. Such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
These statements are not guarantees of future performance and are subject to
several factors, risks and uncertainties, the impact or occurrence of which
could cause actual results to differ materially from the expected results
described in the forward-looking statements. These important factors, risks
and uncertainties include (i) fluctuations in general business cycles for
commercial aircraft, military aircraft, space and defense products, industrial
capital goods and medical devices, (ii) our dependence on government contracts
that may not be fully funded or may be terminated, (iii) our dependence on
certain major customers, such as The Boeing Company, for a significant
percentage of our sales, (iv) the possibility that the demand for our products
may be reduced if we are unable to adapt to technological change, (v) intense
competition which may require us to lower prices or offer more favorable terms
of sale, (vi) our significant indebtedness which could limit our operational
and financial flexibility, (vii) the possibility that new product and research
and development efforts may not be successful which could reduce our sales and
profits, (viii) increased cash funding requirements for pension plans, which
could occur in future years based on assumptions used for our defined benefit
pension plans, including returns on plan assets and discount rates, (ix) a
write-off of all or part of our goodwill, which could adversely affect our
operating results and net worth and cause us to violate covenants in our bank
agreements, (x) the potential for substantial fines and penalties or
suspension or debarment from future contracts in the event we do not comply
with regulations relating to defense industry contracting, (xi) the potential
for cost overruns on development jobs and fixed price contracts and the risk
that actual results may differ from estimates used in contract accounting,
(xii) the possibility that our subcontractors may fail to perform their
contractual obligations, which may adversely affect our contract performance
and our ability to obtain future business, (xiii) our ability to successfully
identify and consummate acquisitions, and integrate the acquired businesses
and the risks associated with acquisitions, including that the acquired
businesses do not perform in accordance with our expectations, and that we
assume unknown liabilities in connection with the acquired businesses for
which we are not indemnified, (xiv) our dependence on our management team and
key personnel, (xv) the possibility of a catastrophic loss of one or more of
our manufacturing facilities, (xvi) the possibility that future terror
attacks, war or other civil disturbances could negatively impact our business,
(xvii) that our operations in foreign countries could expose us to political
risks and adverse changes in local, legal, tax and regulatory schemes, (xviii)
the possibility that government regulation could limit our ability to sell our
products outside the United States, (xix) product quality or patient safety
issues with respect to our medical devices business that could lead to product
recalls, withdrawal from certain markets, delays in the introduction of new
products, sanctions, litigation, declining sales or actions of regulatory
bodies and government authorities, (xx) the impact of product liability claims
related to our products used in applications where failure can result in
significant property damage, injury or death and in damage to our reputation,
(xxi) the possibility that litigation may result unfavorably to us, (xxii) our
ability to adequately enforce our intellectual property rights and the
possibility that third parties will assert intellectual property rights that
prevent or restrict our ability to manufacture, sell, distribute or use our
products or technology, (xxiii) foreign currency fluctuations in those
countries in which we do business and other risks associated with
international operations, (xxiv) the cost of compliance with environmental
laws, (xxv) the risk of losses resulting from maintaining significant amounts
of cash and cash equivalents at financial institutions that are in excess of
amounts insured by governments, (xxvi) the inability to utilize amounts
available to us under our credit facilities given uncertainties in the credit
markets and (xxvii) our customer's inability to pay us due to adverse economic
conditions or their inability to access available credit. The factors
identified above are not exhaustive. New factors, risks and uncertainties may
emerge from time to time that may affect the forward-looking statements made
herein. Given these factors, risks and uncertainties, investors should not
place undue reliance on forward-looking statements as predictive of future
results. We disclaim any obligation to update the forward-looking statements
made in this report.

SOURCE Moog Inc.

Ann Marie Luhr, +1-716-687-4225, for Moog Inc.